CVRx (CVRX) Projected to Post Earnings on Monday

Key Points

• CVRx is expected to release its Q2 2025 earnings on August 4th, with analysts predicting an earnings per share (EPS) of ($0.52) and revenue of $13.22 million.
• In the last earnings report, CVRx posted a loss of ($0.53) EPS, exceeding expectations but falling short on revenue compared to analyst projections.
• CVRx's stock has a current market cap of $217.42 million and has witnessed insider buying, with Director Kirk G. Nielsen acquiring 61,200 shares recently.

CVRx (NASDAQ:CVRX - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Monday, August 4th. Analysts expect CVRx to post earnings of ($0.52) per share and revenue of $13.22 million for the quarter. CVRx has set its FY 2025 guidance at EPS and its Q2 2025 guidance at EPS.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.03. The company had revenue of $12.35 million during the quarter, compared to analysts' expectations of $14.68 million. CVRx had a negative net margin of 97.49% and a negative return on equity of 79.04%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Performance

NASDAQ CVRX opened at $8.34 on Monday. The firm has a 50-day moving average of $6.72 and a 200-day moving average of $9.87. The company has a debt-to-equity ratio of 0.71, a quick ratio of 13.45 and a current ratio of 14.82. The stock has a market cap of $217.42 million, a PE ratio of -3.83 and a beta of 1.23. CVRx has a 52-week low of $4.30 and a 52-week high of $18.55.

Insider Buying and Selling

In other CVRx news, Director Kirk G. Nielsen purchased 61,200 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were acquired at an average cost of $5.23 per share, with a total value of $320,076.00. Following the completion of the transaction, the director owned 1,899,168 shares in the company, valued at $9,932,648.64. The trade was a 3.33% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought 78,666 shares of company stock worth $411,031 over the last 90 days. 18.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

CVRX has been the subject of a number of research reports. Lake Street Capital cut their target price on shares of CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. William Blair upgraded shares of CVRx to a "strong-buy" rating in a research note on Monday, July 7th. Piper Sandler cut their target price on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. JPMorgan Chase & Co. restated an "underweight" rating and set a $7.00 target price (down previously from $15.00) on shares of CVRx in a research note on Friday, May 9th. Finally, Canaccord Genuity Group lowered their price target on shares of CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $14.50.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.